In addition, SH2D1A expression in tumor purity was found to be significantly correlated with the expression of the immune cell markers VSIG4, CD3E, CD2, TBX21, KIR2DS4, CD3D, CD79A, PDCD1, STAT5B, CTLA4, CCR7, HLA-DPA1, CD163, IFNG, CD86, KIR3DL1, HLA-DRA, LAG3, ITGAX, GZMB, CCR8, STAT4, IL13, HAVCR2, CD19, CD1C, CD8A, TNF, MS4A4A, STAT1, KIR2DL4, IL10, HLA-DQB1, FOXP3, STAT5A, CD8B, KIR3DL2, CD68, CCL2, TGFB1, KIR2DL3, ITGAM, HLA-DPB1, PTGS2, IL21, NRP1, CSF1R, IL17A, STAT6, GATA3, KIR3DL3, STAT3, IRF5, and BCL6 (Table 3). The gene discussed is CD86; the disease is neoplasm.